Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Long COVID-19 Syndrome, COVID 19, Noncom...
Phase NA
Enrollment 374
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19. Researchers will compare a structured rehabilitation program to informational support through evidence-based messages to determine if rehabilitation leads to better functional and cognitive outcomes in patients with Long Covid-19. Participants will be randomly assigned to one of two groups: 1. Functional and cognitive rehabilitation: Attending weekly in-person sessions for 8 weeks, including supervised physical and cognitive exercises. 2. Informational support: Receiving weekly evidence-based educational messages for 8 weeks. Participants will undergo assessments at baseline, post-intervention, and six months later, including a six-minute walk test, handgrip strength measurement, and questionnaires on disability, anxiety, depression, fatigue, dyspnea, cognitive function, and quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Functional and cognitive rehabilitation strategy — The functional and cognitive rehabilitation strategy is a structured, supervised program, designed to improve physical and cognitive function in patients with Long Covid-19 and chronic diseases. Participants will attend weekly in-person sessions for 8 weeks at study sites. Each session includes: * Functional Rehabilitation (60 min): Warm-up, aerobic exercise (elliptical/treadmill), muscle strengthening, and cool-down, all supervised by trained healthcare professionals who monitor effort levels and heart rate. * Cognitive Rehabilitation (30 min): Memory, attention, and executive function exercises, guided by occupational therapists or speech therapists.
  • Other: Evidence-Based Informational Support — The evidence-based informational support intervention provides structured, research-based health information to patients with Long Covid-19 and chronic diseases. Participants receive weekly digital messages for 8 weeks via email or text, covering key topics such as Covid-19 prevention, treatment, follow-up, and prognosis. Content is derived from high-quality scientific studies and clinical guidelines. A total of 24 informational pieces are delivered, ensuring comprehensive coverage of essential health recommendations. This intervention is remote, accessible, and designed to enhance patient knowledge and self-management, distinguishing it from traditional in-person education programs.

Primary Outcomes

  • Composite Change in Functional Capacity, Cognitive Function, Health-Related Quality of Life, and Strength (Baseline (Day 1), 4 weeks post-intervention, and 6-month follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-30
Completion: 2027-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 374 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundación Cardioinfantil Instituto de Cardiología
Collaborators: Hospital Militar Central, Colombia
Contact Information
Study Contact:
Karen J Moreno, PT MSc
+6016672727
kmoreno@lacardio.org
Karen J Moreno, PT MSc
+6016672727
kmoreno@lacardio.org
Fundación Cardioinfantil-Instituto de cardiología
Interventions
  • Other: Functional and cognitive rehabilitation strategy — The functional and cognitive rehabilitation strategy is a structured, supervised program, designed to improve physical and cognitive function in patients with Long Covid-19 and chronic diseases. Participants will attend weekly in-person sessions for 8 weeks at study sites. Each session includes: * Functional Rehabilitation (60 min): Warm-up, aerobic exercise (elliptical/treadmill), muscle strengthening, and cool-down, all supervised by trained healthcare professionals who monitor effort levels and heart rate. * Cognitive Rehabilitation (30 min): Memory, attention, and executive function exercises, guided by occupational therapists or speech therapists.
  • Other: Evidence-Based Informational Support — The evidence-based informational support intervention provides structured, research-based health information to patients with Long Covid-19 and chronic diseases. Participants receive weekly digital messages for 8 weeks via email or text, covering key topics such as Covid-19 prevention, treatment, follow-up, and prognosis. Content is derived from high-quality scientific studies and clinical guidelines. A total of 24 informational pieces are delivered, ensuring comprehensive coverage of essential health recommendations. This intervention is remote, accessible, and designed to enhance patient knowledge and self-management, distinguishing it from traditional in-person education programs.
Study Locations (1 sites)
Fundación Cardioinfantil-Instituto de cardiología, Bogotá, Bogotá DC 110131 Colombia
Eligibility Criteria
Inclusion Criteria: * Covid-19 confirmed. * History of arterial hypertension or diabetes mellitus before entering the institutional registries of the FCI-IC or HOMIL, institutional registries of the FCI-IC or HOMIL or before having the diagnosis of SARSCoV-2 infection. * Persistence of two or more concurrent symptoms, related to Covid-19 prologue, for at least 4 weeks (persistent, intermittent, or intermittent). * At least one of these symptoms must have an impact on activities of daily living. They can be physical (fatigue, dyspnea, myalgias, arthralgias) or neuropsychiatric (cognitive, sleep and emotional alterations). * Symptoms unexplained by underlying disease or other condition concomitant with SARS-CoV-2 infection. SARS-CoV-2 infection (determined by prior medical history review and participant interview). participant interview). \- Ability to read and attend functional and cognitive rehabilitation sessions or to receive the with evidence-based informational messages. Exclusion Criteria: * Age \>80 years. * Severely advanced baseline comorbidities prior to SARS-CoV-2 infection. * Presence of chronic respiratory disease (partial or permanent supplemental oxygen use), cardiac failure (LVEF\<40%) or advanced renal disease (GFR\<30%). heart failure (LVEF\<40%) or advanced renal disease (GFR\<30). * Two hospitalizations in the year prior to admission to the institutional registries of the FCI-IC and the HOMIL for the patient's underlying disease. * Dependence on a caregiver. * Orthopedic or cardiopulmonary problems that contraindicate the performance of aerobic exercise. * Neuropsychiatric or cognitive limitations that limit understanding or following commands and performing attention exercises.
Conditions Glaucoma
Phase Not Applicable
Enrollment 16
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • the agreement between 10-2 HFA and 24-2c HFA in detecting central visual field defect (12 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-05-04
Completion: 2029-05-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione G.B. Bietti, IRCCS
Contact Information
Study Contact:
Gloria Roberti, PhD
+390685356727
gloria.roberti@fondazionebietti.it
IRCCS-Fondazione GB Bietti
Gianluca Manni, MD
+3906209001
gianlucamanni53@gmail.com
University of Rome Tor Vergata
Interventions
N/A
Study Locations (2 sites)
IRCCS-Fondazione GB Bietti, Rome, Italy
University of Rome Tor Vergata, Rome, Italy
Eligibility Criteria
Inclusion Criteria: * glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness Exclusion Criteria: * age\<18 years * unable to read, understand and sign the written informed consent * unable to perform visual field test * advanced glaucoma with C/D\>0.7 * other causes of optic neuropathies * retinal or macular diseases * lens or corneal opacities * spherical refractive defect \>± 6D * cylindric refractive defect \>± 3D
Conditions Healthy, Menopause, Hypertension, Inflam...
Phase NA
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical study in women after menopause is to investigate whether the daily intake of nitrate from beetroot juice over 12 weeks enhances the positive effect of exercise training on vascular function, blood pressure and physical performance. The risk of cardiovascular diseases (CVD) increases with advancing age and women are particularly affected. In women, the decline in the sex hormone oestrogen in the blood circulation with menopause contributes to impaired vascular function and an increased CVD risk; in part through increased inflammatory processes, oxidative stress, and a reduced body's own production of nitric oxide (NO). NO is a signaling molecule that is important for vascular function. Endurance-based exercise training is a key lifestyle strategy to prevent CVD. However, studies indicate that exercise is less effective in terms of its health-promoting adaptations in women after menopause as compared with men of similar age. This study investigates the effect of exercise training in combination with the intake of nitrate-rich beetroot juice on functions of the cardiovascular system. Nitrate is a nitrogen compound that is found naturally in plant foods (e.g. beetroot juice) and is converted to NO in the human body. Results of previous studies indicate vasodilatory, blood pressure-lowering and performance-enhancing effects as well as positive influences on inflammatory processes and oxidative stress following nitrate intake. The hypothesis is that nitrate intake concomitant to training promotes training adaptations and further improves vascular function, blood pressure and physical performance compared to training without nitrate intake. For the study, 54 untrained postmenopausal women (with the ages between 45 and 65 years) will be recruited and randomly allocated into two groups. Both groups will undergo 12 weeks of endurance-based exercise training. One group will receive nitrate-rich beetroot juice, and the other nitrate-depleted beetroot juice (as placebo). Vascular function, blood pressure, maximum oxygen uptake, and blood biomarkers for nitrate metabolism, inflammation status and oxidative stress will be examined. The anticipated study results will provide new insights into whether nitrate as a 'training adjunct' improves health-promoting training adaptations in women after menopause. The overall aim is to improve the cardiovascular health and performance of middle-aged women and reduce their increased CVD risk.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Nitrate group — Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
  • Dietary Supplement: Placebo group — Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.

Primary Outcomes

  • Forearm blood flow (FBF) response to acetylcholine (FBFACh) (Change from baseline FBFACh to after the 12-week intervention period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-31
Completion: 2027-03
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Vienna
Collaborators: Medical University of Vienna, Danube University Krems, University of Giessen, Edith Cowan University, Flinders University
Principal Investigators:
  • Oliver Neubauer, Dr.Priv.Doz. (PRINCIPAL_INVESTIGATOR) - University of Vienna
Contact Information
Study Contact:
Oliver Neubauer, Dr.Priv.Doz.
+4314277
oliver.neubauer@univie.ac.at
Michael Wolzt, Prof.Dr.med.
+43140400
michael.wolzt@meduniwien.ac.at
Oliver Neubauer, Dr., Priv.-Doz. (PD)
+43-1-4277-54933
oliver.neubauer@univie.ac.at
University of Vienna
Interventions
  • Dietary Supplement: Nitrate group — Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
  • Dietary Supplement: Placebo group — Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
Study Locations (1 sites)
University of Vienna, Vienna, State of Vienna 1090 Austria
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women (amenorrhoeic ≥1 year), between the ages of 45 and 65 years, inclusive, who are either normotensive or are medically treated for stage 1 hypertension * Written informed consent Exclusion Criteria: * Current or recent (within previous 3 months) engagement in exercise training (i.e., planned, structured, and regular exercise) with an average net exercise time of \>2 hours per week * Above-average cardiorespiratory fitness levels (i.e., a V̇O2 max max above the 75th percentile of age- and sex-specific normative data: ≥43 mL/kg/min for women aged 45-49 years, ≥38 mL/kg/min for women aged 50-59 years, ≥35 mL/kg/min for women aged 60-65 years) * Any evidence of acute or chronic diseases such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) \<50 mL/min), pulmonary, neural, or musculoskeletal disease, osteoporotic fractures, cancer, or type 1 or 2 diabetes mellitus * Fasting glucose \>7.0 mmol/L or HbA1c \> 6.5 rel. % * BMI \<18.5 kg/m2 or \>30kg/m2 * A mean 24-hour ambulatory systolic/diastolic blood pressure of ≥130/80 mm Hg * Irregular resting electrocardiography (ECG) * Inability to perform physical exercise * Abnormal cardiovascular responses during the baseline V ̇O2 max test, including symptoms, ECG abnormalities, arrhythmias, or exaggerated blood pressure responses * Current or recent (\<12 months) oestrogen-based hormone-replacement therapy * Chronic use of nitric oxide (NO) donors, organic nitrites/nitrates, Ticagrelor, sodium-glucose cotransporter 2 (SGLT2) inhibitors, high-dose statins (i.e., Simvastatin \>40mg/day, Atorvastatin \>20mg/day, Rosuvastatin \>10mg/day), acetylsalicylic acid \>100mg/day, non-steroidal anti-inflammatory drugs (NSAID) * A change in drug therapy likely to influence major outcomes within the previous 2 months, or likelihood that drug therapy would change during the study * Use of antibiotics (within previous 2 months) * Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouthwash for a period of 4 weeks before randomization will be included) * Being vegan or vegetarian or consumption of \>5 serves of vegetables per day * Current or recent (within previous 6 months) significant (\>6%) loss or gain of body weight * Current or recent (\<12 months) regular smoking of \>5 cigarettes per day * Alcohol intake of \>70 g per week and/or binge drinking behaviour * Inability or unwillingness to follow the study protocol
Conditions Hypertension, Hypertension Complicated
Phase NA
Enrollment 16895
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

High blood pressure (BP) or hypertension (HTN) affects over 100 million individuals in the US, increasing the risk of adverse outcomes, including stroke, myocardial infarction (MI), and chronic kidney disease (CKD). Effective therapies include non-pharmacologic approaches and multiple medication classes. Successful HTN management requires ongoing patient engagement for BP monitoring and treatment intensification. Reaching this goal is challenging, and many patients with HTN do not have controlled BP. Using a collaborative partnership between patients, clinicians, health system and public health stakeholders, and the research team the investigators plan to overcome barriers to widespread implementation of evidence-based health system strategies to improve BP control in a large, urban, primary care-based safety-net setting for diverse populations experiencing disparities in HTN-related outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: RBPM — Standardized blood pressure measurement and treatment protocols in clinical practice.
  • Other: MII — Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.

Primary Outcomes

  • Systolic blood pressure (SBP) improvement (Baseline, every 3 months up to 54 months)
  • Interventions received (Baseline, 54 months)
  • Patient activation (Baseline, 18 months, 30 months, 36 months, 42 months, 54 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-08
Completion: 2029-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 16895 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston Medical Center
Collaborators: Patient-Centered Outcomes Research Institute, Boston Healthcare for the Homeless Program (BHCHP), Boston Medical Center General Internal Medicine primary care (BMC GIM), Boston Medical Center Family Medicine Primary Care (BMC FM), NeighborHealth Center Family Medicine at Maverick Street (NH FM), NeighborHealth Center Internal Medicine at Gove Street (NH IM), NeighborHealth South End (NH South End), Manet Community Health Center (Maner CHC), Mattapan Community Health Center (Mattapan), Greater Roslindale Medical and Dental Center (GRMDC), Boston University School of Public Health (BUSPH), BUSPH Biostatistics and Epidemiology Data Analytics Center (BEDAC)
Principal Investigators:
  • Michael Fischer, MD MS (PRINCIPAL_INVESTIGATOR) - Boston Medical Center, Internal Medicine
  • Cheryl Clark, MD ScD (PRINCIPAL_INVESTIGATOR) - Institute for Health Equity Research, Evaluation & Policy, MA League of CHCs
Contact Information
Study Contact:
Michael Fischer, MD MS
(617) 414-7288
Michael.Fischer@bmc.org
Justine Scott, MPH
(617) 414-7288
Justine.Scott@bmc.org
Interventions
  • Behavioral: RBPM — Standardized blood pressure measurement and treatment protocols in clinical practice.
  • Other: MII — Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.
Study Locations (7 sites)
Boston Healthcare for the Homeless (BHCHP), Boston, Massachusetts 02118 United States
Boston Medical Center Family Medicine, Boston, Massachusetts 02118 United States
Boston Medical Center, General Internal Medicine primary care, Boston, Massachusetts 02118 United States
Neighborhood Health, Boston, Massachusetts 02118 United States
Mattapan Community Health Center, Boston, Massachusetts 02126 United States
Manet Community Health Center, Quincy, Massachusetts 02169 United States
Greater Roslindale Medical and Dental Center (GRMDC), Roslindale, Massachusetts 02131 United States
Eligibility Criteria
Inclusion Criteria: * Adult (age\>18) patients receiving primary care at one of the 9 participating sites, with primary care provider (PCP) visit in the preceding year * Presence of HTN defined by one or more of: 1) diagnosis included on active problem list, 2) active HTN medications in prior year, 3) 3 separate elevated BP measurements * Uncontrolled HTN defined as systolic blood pressure (SBP)\>140 Exclusion Criteria: * Not meeting the inclusion criteria
Conditions Pulmonary Arterial Hypertension
Phase PHASE1, PHASE2
Enrollment 90
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Biological: HS235 — Subcutaneous Injection
  • Other: Placebo — Subcutaneous Injection

Primary Outcomes

  • Incidence and Number of Adverse Events (AEs) (up to 29 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-08-19
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: 35Pharma Inc
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
Interventions
  • Biological: HS235 — Subcutaneous Injection
  • Other: Placebo — Subcutaneous Injection
Study Locations (4 sites)
Investigational Site-102, Tampa, Florida 33620 United States
Investigational Site-104, Providence, Rhode Island 02903 United States
Investigational Site-305, Barcelona, 08035 Spain
Investigational Site-903, London, London W12 0HS United Kingdom
Eligibility Criteria
Inclusion Criteria: Participants are eligible to be included in the study only if they meet all of the following criteria: 1. Male and female participants, 18 years of age and older. 2. Body Mass Index (BMI) 18.5 and 40 kg/m2 and body weight at or below 120 kg. 3. Baseline RHC performed during the Screening Period documenting: 1. A minimum PVR of ≥ 5 Wood units (WU) or ≥ 400 dyn·sec·cm-5 and, 2. A pulmonary artery wedge pressure (PAWP) of ≤ 15 mm Hg. 4. Diagnosis of WHO pulmonary arterial hypertension (PAH) Group 1. 5. Symptomatic PAH classified as WHO Functional class II to IV. 6. On stable doses of at least 2 approved background PAH therapies and diuretics. 7. 6-Minute Walk Distance (6MWD) ≥ 150 m and ≤ 500 m repeated twice during screening. 8. Ability to adhere to study visit schedule and understand and comply with all protocol requirements. Exclusion Criteria: 1. PH WHO Groups 2, 3, 4 or 5. 2. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening. 3. Any symptomatic coronary disease events. 4. History of heart transplant or on heart transplant list. 5. Uncontrolled systemic hypertension. 6. History of restrictive, constrictive or congestive cardiomyopathy. 7. History of significant mitral regurgitation or aortic regurgitation valvular disease. 8. Untreated or poorly controlled moderate or severe obstructive sleep apnea. 9. A diagnosis of worse than moderate COPD or worse than mild ILD. 10. Cerebrovascular event within 90 days prior to screening 11. A pneumonectomy or lobectomy 12. Having received an activin signaling inhibitor such as sotatercept at any time prior to screening 13. A Hgb \> sex-specific ULN 14. Platelets count \< 100,000/mm3 15. Severe (stage ≥4) renal failure with eGFR \< 30 mL/min/m2 16. Abnormally elevated liver function enzymes (ALT or AST \> 3X ULN, or total bilirubin \> 1.5X ULN).
Conditions Glaucoma
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The GLASS Study is designed to help researchers learn whether repeating a non-invasive laser treatment called DSLT (Direct Selective Laser Trabeculoplasty) can better control eye pressure in patients with early-stage glaucoma or ocular hypertension. All participants will receive the laser treatment in both eyes. After three months, one eye will be randomly selected to receive a second treatment, while the other eye will serve as a comparison. The goal is to see whether two treatments work better than one at keeping eye pressure low without using daily eye drops. This study will help doctors decide the best way to use this laser treatment to manage glaucoma and delay the need for medication. Participants will be followed for one year to monitor safety, eye pressure, and the need for any additional treatments.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT) — This is the first clinical study to evaluate repeat bilateral Direct Selective Laser Trabeculoplasty (DSLT) in treatment-naïve patients, using a paired-eye design. Unlike prior SLT studies, which focused on monocular treatment or repeat treatment following IOP rebound, this study randomizes one eye to receive a second DSLT treatment three months after the first, while the fellow eye receives only a single treatment. This allows for a direct intra-subject comparison of efficacy and durability. Existing studies, including GLAUrious and LiGHT, suggest the potential benefits of repeat laser, but no data currently exist for early, scheduled repeat treatment with DSLT. This trial uniquely investigates whether proactively repeating the procedure in a controlled eye extends IOP reduction and delays or reduces the need for topical medications.

Primary Outcomes

  • Mean Decrease in Intraocular Pressure (IOP) from Baseline (Baseline to Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06
Completion: 2027-08
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Twin Cities Eye Consultants
Collaborators: Alcon Research
Principal Investigators:
  • George R Wandling, MD (PRINCIPAL_INVESTIGATOR) - Twin Cities Eye Consultants - Partner
Contact Information
Study Contact:
Hannah Schoenecker
612-999-2020
research@tcecmn.com
Study Coordinator
612-999-2020
research@tcecmn.com
Twin Cities Eye Consultants
George R Wandling, MD
Twin Cities Eye Consultants
Interventions
  • Device: Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT) — This is the first clinical study to evaluate repeat bilateral Direct Selective Laser Trabeculoplasty (DSLT) in treatment-naïve patients, using a paired-eye design. Unlike prior SLT studies, which focused on monocular treatment or repeat treatment following IOP rebound, this study randomizes one eye to receive a second DSLT treatment three months after the first, while the fellow eye receives only a single treatment. This allows for a direct intra-subject comparison of efficacy and durability. Existing studies, including GLAUrious and LiGHT, suggest the potential benefits of repeat laser, but no data currently exist for early, scheduled repeat treatment with DSLT. This trial uniquely investigates whether proactively repeating the procedure in a controlled eye extends IOP reduction and delays or reduces the need for topical medications.
Study Locations (1 sites)
Twin Cities Eye Consultants, Coon Rapids, Minnesota 55433 United States
Eligibility Criteria
Inclusion Criteria: * Male and female patients aged 40 years or older * A bilateral diagnosis of ocular hypertension, glaucoma suspect, or mild primary open angle glaucoma as defined by AAO PPP * Treatment naïve with an unmedicated IOP between 21-35 mmHg, inclusive, and within +/- 3mmHg of each eye to be eligible * BCVA of 20/50 or better * The subject is able to read and understand the requirements of the study and provide written informed consent. * The subject is willing to follow study instructions, agrees to comply with all study procedures and attend all scheduled follow-up exams for 12 months after the initial treatment. Exclusion Criteria: * Unable to view scleral spur inferiorly with gonioscopy. * Congenital or developmental glaucoma, angle closure glaucoma, secondary glaucoma (e.g. exfoliative, pigmentary, etc.) pigmentary, neovascular glaucoma, closed angle glaucoma, or uveitic glaucoma. * Use of oral or ocular hypotensive medication for glaucoma. * Prior history of ocular surgery except for cataract surgery (must be ≥ 2 years prior) * Clinically significant ocular pathology, other than cataract and glaucoma, including but not limited to neovascular age-related macular degeneration, advanced dry macular degeneration, and proliferative diabetic retinopathy, etc. * Clinically significant ocular inflammation or infection within 6 months prior to screening. * Previous corneal transplant or clinically significant corneal dystrophy, e.g., Fuch's dystrophy (≥12 confluent guttae) * Unclear ocular media prevent visualization of the fundus or anterior chamber angle. * Uncontrolled systemic disease that in the opinion of the Investigator would put the subject's health at risk and/or prevent the subject from completing all study visits. * Current participation in another investigational drug or device clinical trial (which includes the fellow eye) within the past 30 calendar days. * Pregnant or nursing women; or women of childbearing age not using medically acceptable contraceptives. Accepted prior ocular procedures: * Cataract surgery (if ≥ 2 years or screening) * YAG capsulotomy (if ≥ 60 days of screening)

Mepitel Film Breast

NCT07729423
Recruiting
Conditions Breast Cancer, Radiation Dermatitis
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Primary Objective To examine the tolerability of Mepitel Film in the prevention of RD patients undergoing whole breast or chest wall RT in the hot and humid weather in Singapore Secondary Objectives To evaluate the incidence of acute radiation dermatitis, quality of life, satisfaction, and cost analysis of Mepitel Film use.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Frequency of total replacement of Mepitel Film or "touch-up" when compared with the data from the RCT in Ontario, Canada (From first day RT to the 2 weeks post RT)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-12
Completion: 2029-06-30
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University Hospital, Singapore
Collaborators: Molnlycke Health Care AB
Principal Investigators:
  • Wee Yao Koh, MBBS (PRINCIPAL_INVESTIGATOR) - National University Hospital, Singapore
Contact Information
Study Contact:
Shing Fung Lee, MBBS
+6567726392
leesf@nuhs.edu.sg
Qian Yee Chai, BSc
+6567723077
queenie_qy_chai@nuhs.edu.sg
Qian Yee Chai, BSc
+6567723077
queenie_qy_chai@nuhs.edu.sg
National University Hospital
Interventions
N/A
Study Locations (1 sites)
National University Hospital, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * Age ≥ 21 years old (legal age of maturity in Singapore) * Male or female * Informed consent * Patients have undergone a mastectomy with or without reconstruction or breast-conserving surgery. * Histological confirmation of breast carcinoma (invasive or in situ carcinoma) * Patients are scheduled to receive hypofractionated (40Gy in 15 daily fractions or 26Gy in 5 daily fractions) photon-based RT * Patient treated with or without tissue the addition of equivalent bolus and/or boost. * Can communicate in English or be aided by a translator. Exclusion Criteria: * Prior RT to any portion of the planned treatment site. * Patients will receive partial breast external beam RT, proton beam therapy, or brachytherapy. * Patients with active rash, pre-existing dermatitis, or other conditions within the treatment area may make skin assessment for the study difficult per treating physician discretion. * Known history of adhesive, tape or silicon allergy or sensitivity. * Concomitant cytotoxic chemotherapy * Bilateral breast pathology requiring concurrent bilateral breast or chest wall RT. * Current inflammatory breast cancer or gross dermal involvement at initiation of RT. * Patient has a Karnofsky Performance Status score \<60.
Conditions Metastatic Breast Cancer
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic breast cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease and expectations, and to provide a blood sample and an archival tumor biopsy. In HOPE Focus these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will enumerate future therapeutic options that match patient history and his genomic profile, when feasible. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years. The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic breast cancer patients.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Genetic: Liquid Biopsy — Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy
  • Genetic: Archival Tumor DNA — Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis

Primary Outcomes

  • To evaluate the feasibility of incorporating a molecular diagnosis in the management of patients with metastatic breast cancer following a patient-centric strategy. (Ongoing basis during 5 years of study duration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-20
Completion: 2030-05-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Roche Farma, S.A, Menarini Group, AstraZeneca, Pfizer, Eli Lilly and Company
Contact Information
Study Contact:
HOPE Focus Study Team
(+34) 93 343 63 02
focus.hope@gruposolti.org
SOLTI Cancer Research Group
Interventions
  • Genetic: Liquid Biopsy — Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy
  • Genetic: Archival Tumor DNA — Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
Study Locations (1 sites)
SOLTI Cancer Research Group, Barcelona, Barcelona 08008 Spain
Eligibility Criteria
Inclusion Criteria: 1. Female or male patients residing in Spain. 2. Age ≥ 18 years. 3. Signed informed consent prior to any study-related procedures, except for registration. 4. Self-reported Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 5. Patients with metastatic breast cancer in at least one of these situations: 1. Patients recently diagnosed with ER+/HER2- metastatic breast cancer as a recurrence during adjuvant treatment and prior to initiating any treatment in the metastatic setting. 2. Patients with metastatic breast cancer of any subtype that have progressed after at least one line of treatment in the metastatic setting. Exclusion Criteria: 1. Presence of a condition or abnormality that, in the opinion of the investigators, would compromise the safety of the patient or the quality of the data. 2. Inability or refusal to commit with the procedures of the study at the moment of inclusion. 3. More than 3 prior systemic chemotherapy or antibody-drug conjugate (ADC) regimens for metastatic disease. Note: treatments for bone metastases (eg, bisphosphonates, denosumab, etc.), targeted therapies (eg, PARP inhibitors, CDK 4/6 inhibitors, immunotherapy etc.) and hormonal therapy are not considered as prior systemic chemotherapy treatments for advanced disease.
Conditions Breast Cancer, Cancer of the Breast
Phase PHASE2
Enrollment 81
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: VENTANA MIB-1 Ki67 assay — Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.
  • Device: Oncotype DX® Recurrence Score — Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.
  • Device: PAM50-based Prosigna breast cancer gene signature assay — This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.
  • Drug: Anastrozole — Standard of care. All patients must start on anastrozole at time of enrollment but may switch to another aromatase inhibitor (letrozole or exemestane) due to toxicity or financial/other concerns at discretion of investigator after a discussion with the PI. Every effort to minimize interruption of aromatase inhibitor (AI) therapy is recommended.
  • Drug: Combination anthracycline and/or taxane based treatment — Standard of care

Primary Outcomes

  • Objective response rate (ORR) by breast MRI in the combined low-risk plus high-risk endocrine-sensitive groups (pooled endocrine therapy-responders) (Through completion of treatment (estimated to be 6 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-05-30
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 81 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Collaborators: Swim Across America, The Foundation for Barnes-Jewish Hospital
Principal Investigators:
  • Nusayba Bagegni, M.D. (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Nusayba A Bagegni, M.D.
314-273-3022
nbagegni@wustl.edu
Nusayba A Bagegni, M.D.
314-273-3022
nbagegni@wustl.edu
Washington University School of Medicine
Nusayba A Bagegni, M.D.
Washington University School of Medicine
Interventions
  • Device: VENTANA MIB-1 Ki67 assay — Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.
  • Device: Oncotype DX® Recurrence Score — Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.
  • Device: PAM50-based Prosigna breast cancer gene signature assay — This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.
  • Drug: Anastrozole — Standard of care. All patients must start on anastrozole at time of enrollment but may switch to another aromatase inhibitor (letrozole or exemestane) due to toxicity or financial/other concerns at discretion of investigator after a discussion with the PI. Every effort to minimize interruption of aromatase inhibitor (AI) therapy is recommended.
  • Drug: Combination anthracycline and/or taxane based treatment — Standard of care
Study Locations (1 sites)
Washington University School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed newly diagnosed clinical stage II or III (by AJCC 8th edition - at least T2, any N, M0 or if N1+ then any T) ER-positive (ER \> 10%), any PR, and HER2-negative breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal. * HER2 negative must be assessed by FISH or IHC staining 0 or 1+ according to ASCO/CAP guidelines. * A palpable mass is not required; however, tumor size must be either: * ≥2 cm in one dimension by clinical or radiographic examination (WHO criteria), if clinically axillary lymph node negative OR * Measureable (≥10 mm) by modified RECIST v1.1 for breast MRI (see Section 9.0), if histologically confirmed resectable locoregional nodal involvement. * ECOG performance status 0 or 1. * Eligible to receive neoadjuvant aromatase inhibitor, as per treating physician. * Eligible to receive neoadjuvant standard of care anthracycline- and/or taxane-based chemotherapy regimen, as per treating physician. * Able to tolerate breast MRI with intravenous contrast administration. Must be able to complete the applicable MRI screening evaluation form. * Adequate bone marrow and organ function, as determined by the treating physician. * Known history of hepatitis C virus (HCV) infection is permissible provided the patient has been treated and cured. * At least 18 years of age. * Postmenopausal status, defined as one of the following: * Age ≥ 60 years * Age \< 60 with intact uterus and amenorrhea for 12 consecutive months or more * Status post bilateral oophorectomy, total hysterectomy * Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable), and willing and able to comply with scheduled visits and treatment schedule. Exclusion Criteria: * Inflammatory breast cancer (cT4d disease as per AJCC 8th edition). * Locally recurrent or metastatic disease (cM1 disease as per AJCC 8th edition). * Bilateral breast cancer. * Prior systemic therapy for the indexed breast cancer. * Pre-existing Grade ≥2 neuropathy. * Uncontrolled intercurrent illness that would limit compliance with study requirements. * A history of other malignancy ≤5 years prior to the indexed breast cancer diagnosis with the following exceptions: * Basal cell or squamous cell carcinoma of the skin which were treated with local resection only * Adequately treated carcinoma in situ of the cervix. * Prior or concurrent malignancy whose natural history or treatment will not interfere with the safety or efficacy assessments of the indexed breast cancer. In this event, review and approval by the study PI is required. * Concurrent participation in any investigational therapeutic trial for treatment of breast cancer. * Known HIV positivity that in the judgement of the treating physician would impact safety of chemotherapy receipt. * A history of allergic reactions attributed to compounds of similar chemical or biologic composition to anastrozole, taxanes (paclitaxel or nab-paclitaxel), anthracyclines (doxorubicin or epirubicin) or cyclophosphamide. * Evidence of uncontrolled ongoing or active infection, requiring parenteral anti-bacterial, anti-viral, or anti-fungal therapy ≤ 7 days prior to administration of study treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible. * Any uncontrolled medical condition that in the opinion of the Investigator would pose a risk to participant safety or interfere with study participation or interpretation of individual participant results.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

To create a registry (database) of participants who come in for breast MRI scans. Researchers want to use this information to study if participants with dense breast tissue (tissue that is more difficult to see on mammogram).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Questionnaire/Interview — Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.

Primary Outcomes

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 (through study completion; an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-11
Completion: 2029-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Huong Le-Petross, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Huong Le-Petross, MD
713-563-7827
hlepetross@mdanderson.org
Huong Le-Petross, MD
hlepetross@mdanderson.org
MD Anderson Cancer Center
Interventions
  • Behavioral: Questionnaire/Interview — Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
Study Locations (1 sites)
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Participants 50 years of age or younger who has personal history of breast cancer and mammographically dense breast, per ACR Category C and D. * Participants must be 18 years of age or older. * Participants are being seen at MD Anderson for annual surveillance and scheduled for routine screening mammogram and/or DBT, with negative or benign findings. * Participants must not be pregnant or breast-feeding. If a Participant is of childbearing potential and is uncertain if the Participant could be pregnant or may be pregnant or as per local site standard of practice in women undergoing mammogram/DBT and MRI must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). * The Participants breast density must be known based on prior mammogram or agree to have mammogram or DBT prior to enrollment in order to determine breast density. Participants must have mammographically dense breasts based on American College of Radiology \[ACR\] Breast Imaging \[BI\]- Reporting and Data System Atlas (RADS) lexicon categories c or d (heterogeneous or extreme fibroglandular tissue) on their most-recent prior screening mammogram. * Participants must be asymptomatic for breast disease and undergoing routine screening. * Participants must not have untreated breast cancer (DCIS or invasive cancer) or currently undergoing treatment for breast cancer or planning surgery for a high risk lesion (atypical ductal breast hyperplasia \[ADH\], atypical lobular breast hyperplasia \[ALH\], lobular breast carcinoma in situ \[LCIS\], papilloma, radial scar) at the time of enrollment. * Participants on Tamoxifen can be enrolled in registry trial. * BRCA, other genetic mutation carriers or relatives of mutation carriers, and participants at high-risk for breast cancer, as defined by the American Cancer Society (ACS) breast MR screening recommendations (lifetime risk of \>= 20-25%), can participate. These participants may be analyzed as subsets. * Participants must be able to undergo breast MRI with contrast enhancement; Participants unable to undergo breast MRI with contrast enhancement for any reason are ineligible. * No history of untreatable claustrophobia * No presence of non-MRI compatible metallic objects or metallic objects that, in the opinion of the radiologist, would make MRI a contraindication * No history of sickle cell disease * No contraindication to intravenous contrast administration * No known allergy-like reaction to gadolinium or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology (ACR); participants may be eligible if willing to undergo pre-treatment as defined by the institution's policy and/or ACR guidance * No known or suspected renal impairment; requirements for glomerular filtration rate (GFR) prior to MRI as determined by local site standard practice * Weight less than or equal to the MRI table limit * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * metastatic breast cancer * medically unstable * known contraindications to MRI * allergic reactions to paramagnetic contrast agent or severe allergic diathesis * on renal dialysis or renal dysfunction * undergone chemotherapy or hormonal therapy for cancer in previous 6 months * breast surgery or radiotherapy for cancer to the ipsilateral breast within the past 6 months * had a history of serious breast trauma within the past 3 months * pregnant or breastfeeding * have a disability preventing MRI in a prone position * some MR conditional implants such as neurostimulators or cardiac monitors, per institutional procedures and policy.
Conditions Breast Carcinoma
Phase NA
Enrollment 125
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies whether a post-treatment supportive service program can be used to help breast cancer survivors in Western New York (WNY) transition into post-treatment life (survivorship). The post-treatment supportive service program is delivered to breast cancer survivors of WNY. It combines group support sessions and one-on-one (1:1) peer mentoring sessions. The group support sessions include traditional support groups, educational topics/lessons, activities, such as cooking lessons, celebrations, or facility tours, and guest speakers. The 1:1 peer mentoring sessions are held with a long-term breast cancer survivor mentor. The long-term breast cancer survivor mentor helps the mentee get in the practice of performing once monthly self-assessments and create plans to help improve any identified modifiable risk factors. The long-term breast cancer survivor mentor can also help connect the mentee to providers or resources as needed. A post-treatment supportive service program may help Black women breast cancer survivors in WNY transition into survivorship.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Interview — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
  • Other: Support — Attend 1:1 peer mentoring sessions
  • Procedure: Support Group Therapy — Attend survivorship group support sessions

Primary Outcomes

  • Community-clinical linkages (Up to 12 months)
  • Facilitators to implementation (At 6 and 12 months)
  • Barriers to implementation (At 6 and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-21
Completion: 2030-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Roswell Park Cancer Institute
Principal Investigators:
  • Julia Devonish (PRINCIPAL_INVESTIGATOR) - Roswell Park Cancer Institute
Contact Information
Study Contact:
Julia Devonish
716-845-2300
julia.devonish@roswellpark.org
Roswell Park Cancer Institute
Julia Devonish
Roswell Park Cancer Institute
Interventions
  • Other: Interview — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
  • Other: Support — Attend 1:1 peer mentoring sessions
  • Procedure: Support Group Therapy — Attend survivorship group support sessions
Study Locations (1 sites)
Roswell Park Cancer Institute, Buffalo, New York 14263 United States
Eligibility Criteria
Inclusion Criteria: * Ability to speak and read English * At least 18 years of age or older * Live in the Western New York area * Has been diagnosed with breast cancer (any stage) * Has completed primary breast cancer treatments (i.e., systemic, radiation, and/or surgical interventions other than breast reconstruction surgeries) * Mentors are at least one-year post-treatment completion * Mentees are less than one-year post-treatment completion * Note: Individuals who have completed primary breast cancer treatments who are being managed with ongoing hormonal therapies and/or are awaiting breast reconstruction surgery may participate in this study (i.e., these therapies do not meet exclusion criteria) * Note: Although any breast cancer survivor may participate, priority will be given to those who have most recently transitioned into their post-treatment life (or those who report that support was either not offered or was unavailable to them during their less recent transition into post-treatment life) and /or self-identify as African American Exclusion Criteria: * Currently receiving neoadjuvant and/or adjuvant systemic and/or radiations therapies * Unwilling or unable to complete the assessment in English * Are pregnant or nursing * Are unwilling or unable to follow protocol requirements * Note: Individuals who have completed primary breast cancer treatments who are being managed with ongoing hormonal therapies and/or are awaiting breast reconstruction surgery may participate in this study (i.e., these therapies do not meet exclusion criteria)
Conditions Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study is an observational study being carried out in several hospitals. No extra tests or procedures are required beyond those already part of normal medical care. The study is sponsored by the University of Modena and Reggio Emilia and aims to include about 100 patients. The main goal of the study is to better understand the different biological types of breast cancer in patients who have hormone receptor-positive (HR-positive), HER2-negative breast cancer related to BRCA gene mutations. In particular, the study will explore whether these cancers tend to belong to molecular types that may respond less to endocrine or CDK4/6 inhibitor therapy. The study also compares cancers linked to BRCA1 and BRCA2 mutations and investigates whether the different biological types are associated with differences in disease outcomes and response to treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Distribution of intrinsic subtypes in BRCA1 and BRCA2-associated HR+/HER2-negative tumors (through study completion)
  • Overall survival depending on intrinsic subtype (through study completion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-05
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Angela Toss
Contact Information
Study Contact:
Matteo Lambertini, MD
00390594223286
matteo.lambertini@unige.it
Ospedale San Martino di Genova
Claudio Vernieri, MD
00390594223286
claudio.vernieri@istitutotumori.mi.it
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
Antonio Marra, MD
00390594223286
antonio.marra@ieo.it
Istituto Oncologico Europeo di Milano
Interventions
N/A
Study Locations (6 sites)
Ospedale San Martino di Genova, Genova, 16132 Italy
Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, 20133 Italy
Istituto Oncologico Europeo di Milano, Milan, 20141 Italy
Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, 41124 Italy
Istituto Oncologico Veneto IRCCS Padova, Padova, 35128 Italy
Fondazione Policlinico Universitario Agostino Gemelli di Roma, Roma, 00168 Italy
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Patients carrying a pathogenic or likely pathogenic germline variant in BRCA1 or BRCA2 with a histologically confirmed diagnosis of HR+/HER2-negative breast cancer * Patients with available hospital and/or outpatient medical records for clinical data collection * Presence of available formally fixed paraffin-embedded (FFPE) breast tumor tissue (primary or metastatic site) Exclusion Criteria: * None